Sign In
Buy SYBX
$1.20
+0.0500 (+4.35%)
At Close: Jul 31, 2026
Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates
09:57am, Wednesday, 10'th Nov 2021
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 0.00% and 233.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021
10:30am, Friday, 15'th Oct 2021
CAMBRIDGE, Mass., Oct. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two post
Synlogic Appoints Molly Harper as Chief Business Officer
06:30am, Monday, 27'th Sep 2021
CAMBRIDGE, Mass., Sept. 27, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the ap
Synlogic Announces Pricing of Public Offering of Common Stock
11:32pm, Wednesday, 22'nd Sep 2021
CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricin
Synlogic Announces Proposed Public Offering of Common Stock
04:02pm, Wednesday, 22'nd Sep 2021
CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has
Why Are Synlogic Shares Moving Higher Premarket Monday?
08:31am, Monday, 20'th Sep 2021
Synlogic Inc (NASDAQ: SYBX) has announced data from clinical studies evaluating SYNB1618 and SYNB1934 for phenylketonuria (PKU). PKU is a rare genetic disease that manifests at birth and is charact
SYBX Stock: Why It Increased Today
08:20am, Monday, 20'th Sep 2021
The stock price of Synlogic Inc (NASDAQ: SYBX) increased by over 7% pre-market today. This is why it happened.
Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria
06:30am, Monday, 20'th Sep 2021
CAMBRIDGE, Mass., Sept. 20, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positi
Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting
10:29am, Friday, 10'th Sep 2021
CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that i
Synlogic Presents at Global PKU Patient Meeting
10:27am, Friday, 10'th Sep 2021
CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2021 Results - Earnings Call Transcript
11:52am, Thursday, 12'th Aug 2021
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2021 Results - Earnings Call Transcript
Synlogic, Inc. (SYBX) Reports Q2 Loss, Tops Revenue Estimates
10:06am, Thursday, 12'th Aug 2021
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 3.45% and 23.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Synlogic Reports Second Quarter Financial Results and Provides Business Update
06:30am, Thursday, 12'th Aug 2021
CAMBRIDGE, Mass., Aug. 12, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial
Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference
09:00am, Thursday, 05'th Aug 2021
CAMBRIDGE, Mass., Aug. 5, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Comp
CAMBRIDGE, Mass., July 22, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today the publ
